Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 90

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 90
---
, subject to the information and reporting requirements of the Exchange Act and other federal securities laws,
including compliance with the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). The costs of preparing and filing annual
and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders would cause
our expenses to be higher than they would be if we remained privately held.

It may be time consuming,
difficult and costly for us to develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley Act.
We may need to hire additional financial reporting, internal controls and other finance personnel in order to develop and implement appropriate
internal controls and reporting procedures.

Our stock price may be volatile.

The market price of our common
stock is likely to be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our
control, including the following:

    ●
    changes in our industry;

    ●
    competitive pricing pressures;

    ●
    our ability to obtain working capital financing;

    ●
    additions or departures of key personnel;

    ●
    limited “public float” in the hands of a small number of persons whose sales or lack of sales could result in positive or negative pricing pressure on the market price for our common stock;

    ●
    sales of our common stock;

    ●
    our ability to execute our business plan;

    ●
    operating results that fall below expectations;

    ●
    loss of any strategic relationship;

    ●
    regulatory developments;

    ●
    economic and other external factors;

    ●
    period-to-period fluctuations in our financial results; and

    ●
    inability to develop or acquire new or needed technology or products.

In addition, the securities
markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of
particular companies. These market fluctuations may also materially and adversely affect the market price of our Common Stock.

52

You may have difficulty trading and obtaining
quotations for our common stock.

Our securities are not actively
traded, and the bid and asked prices for our common stock may fluctuate widely. As a result, investors may find it difficult to dispose
of, or to obtain accurate quotations of the price of, our securities. This severely limits the liquidity of the common stock and would
likely reduce the market price of our common stock and